An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
This is an open-label, randomized trial in relapsed refractory subjects with mantle cell lymphoma (MCL).
Inclusion Criteria:
Exclusion Criteria:
Buenos Aires, Buenos Aires C1406FWZ, Argentina
Vila Buarque, São Paulo 01221-010, Brazil
Porto Alegre - RS, 90610-000, Brazil